ESPR on the 120-minute chart is surging with momentum from an FDA approval for a new
cholestrol and lipid medication which will be an alternative to the at statin class which has
side effects and can cause diabetes. I am familar with a few of the professionals on the
science advisory board they are researchers and academics of the highest claiber. The...
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated...
NASDAQ:ESPR Esperion Therapeutics Inc.
Long term PTs 39 - 53 - 76 and higher
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for...
Stocks that are reporting earnings in 3 to 4 weeks can be monitored for pre-earnings runs.
ESPR had momentum runs recently, as marked by the candlestick patterns within the green rectangles in this chart. A shift of sentiment can be seen in the bottoming pattern with Accumulation/Distribution indicators (the area between the blue rectangles).
Often, when...
On the above 3-week chart price action for Esperion Therapeutics has collapsed over 90% since the sell signal in early 2018. Now is an excellent moment to be dollar cost averaging into a long position. Why?
1) A fantastic ‘buy’ signal. Remember this is a 3-week chart. Very powerful on this scale, look left.
2) Long term price action and RSI resistance...
Market Cap: 370 M
Shares Outstanding: 28.2M
Average Trading Volume (10 days): 451K
Shares Short: 28 M
Short Interest(%): 31.4%
Days to cover: 15.4
Change in Short Interest: -35
Ownership Breakdown:
Institutions: 93.1%
General Public:
Hedge Funds: 5.6%
Individual insiders: 1.3%
Sum: 100%
Option profile:
Total OI:
Put Call Ratio:0.63
Put OI:
Call OI:
Highest...
I think ESPR could start to get interested in this level .
- After a long decline from the peak ($ 40) this year, on 27/1/2021, we are now witnessing a consolidation in the price level.
- I do not look at fundamental information, only technical data .
Indicators :
* EMA21 is the purple line
* EMA9 is the green line
* Consolidation at Slow Stochastic
* RSI...
Looks like the pattern is completing, now i expect either a total reversal or a consolidation. All these options are bullish. Comment what you think below. Don't forget to click the like if you do. Thank you.
